Cargando…

The effect of CYP2C92, CYP2C93, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah

Polymorphism in the genes encoding CYP2C9 enzyme and VKORC1 reductase significantly influence warfarin dose requirement since patients with CYP2C9*2, CYP2C9*3 and VKORC1 mutant alleles require lower warfarin maintenance doses. Studies have reported the ethnic variations in the frequency of these gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hosseinkhani, Zohreh, Sadeghalvad, Mona, Norooznezhad, Fathemeh, Khodarahmi, Reza, Fazilati, Mohammad, Mahnam, Azadeh, Fattahi, Ali, Mansouri, Kamran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040167/ https://www.ncbi.nlm.nih.gov/pubmed/30065771 http://dx.doi.org/10.4103/1735-5362.235165

Ejemplares similares

Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes
por: Johnson, Mark, et al.
Publicado: (2014)

Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe
por: Buzoianu, Anca D, et al.
Publicado: (2012)

A PCR method for VKORC1 G-1639A and CYP2C9 A1075C genotyping useful to warfarin therapy among Japanese
por: Tamura, Takashi, et al.
Publicado: (2014)

The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study
por: Forgerini, Marcela, et al.
Publicado: (2023)

Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report
por: Aldiban, Weam, et al.
Publicado: (2022)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017)

Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin
por: da Silveira, Maria Mariana Barros Melo, et al.
Publicado: (2019)

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
por: Haug, Kari Bente Foss, et al.
Publicado: (2008)

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
por: Park, Sea Mi, et al.
Publicado: (2013)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
por: Poopak, Behzad, et al.
Publicado: (2015)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
por: Jorgensen, Andrea L., et al.
Publicado: (2012)

Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
por: Shafique, Huma, et al.
Publicado: (2022)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

Polymorphism of the CYP2C9 and VKORC1 genes: a comment
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
por: Takeuchi, Fumihiko, et al.
Publicado: (2009)

Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia
por: Giraldo-Ocampo, Sebastian, et al.
Publicado: (2023)

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
por: Henderson, Lindsay M., et al.
Publicado: (2019)

The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population
por: Razavi, Fariba Emadian, et al.
Publicado: (2017)

Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2018)

The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
por: Khaleqsefat, Esmat, et al.
Publicado: (2020)

Prosthetic valve thrombosis – association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes
por: SR, Kalpana, et al.
Publicado: (2019)

Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China
por: Yang, Dan, et al.
Publicado: (2018)

Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit
por: Biswas, Mansij, et al.
Publicado: (2018)

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis
por: Zhang, Jinhua, et al.
Publicado: (2016)

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
por: Agrawal, Saaket, et al.
Publicado: (2020)

Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
por: Vasilyev, Filipp Filippovich, et al.
Publicado: (2016)

Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia
por: Alzahrani, Abdullah M., et al.
Publicado: (2013)

Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis
por: Takeuchi, Masanobu, et al.
Publicado: (2016)

Functional characterization of the defective CYP2C9 variant CYP2C9*18
por: Liu, Jian, et al.
Publicado: (2021)

VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients
por: Misasi, Silvia, et al.
Publicado: (2016)

VKORC1 and CYP2C9 Polymorphisms: A Case Report in a Dutch Family with Pulmonary Fibrosis
por: Wijnen, Petal, et al.
Publicado: (2019)

Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement
por: Kaur, Anupriya, et al.
Publicado: (2013)

A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
por: Lee, Soo-Youn, et al.
Publicado: (2005)

CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement
por: Kim, Young Bum, et al.
Publicado: (2012)

The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)‐Warfarin
por: Wanounou, Maor, et al.
Publicado: (2022)

Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
por: Altawil, Yara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i664uv9b0jaqpoebrajt74jr0g